In AD transgenic mice, hippocampal mitochondria show reduced Complex I activity, elevated reactive oxygen species, and fragmented morphology even before plaque formation
Emphysema (mouse model): Intraperitoneal GHK-Cu attenuated cigarette-smoke-induced emphysema and reduced inflammatory cytokines across the same dose range (PMID 35936787)
Activity modification during the healing phase allows tissue repair without constant re-injury
Some limitations that prevent findings from being replicated include failure to report the duration of follow-up (or short follow-up periods), examination of specific lesions types, for example, endometrioma or deep lesions only, and failure to report if excision was complete, thus bringing into question the possibility of residual, rather than recurrent disease [8]
Benefits and Advantages Governed primarily by state boards of pharmacy rather than federal manufacturing regulations Typically meet minimum industry standards set by USP Overall lower regulatory risk compared to 503B May have a greater number of formulation offerings due to lower development costs, allowing for a wider variety of dosing options and formulations Lower initial startup cost compared to starting a 503B Lower operational requirements compared to 503Bs Faster time to market for new compounding services Lower annual fees (primarily state licensing fees, compared to significant annual FDA establishment and potential reinspection fees for 503Bs) Can focus on developing a local business or scaling and targeting the broader market Personalized patient care, tailored formulations for specialized treatment plans and patient needs, consultation opportunities Significant growth and scale-up opportunities Strong revenue potential through niche markets and personalized formulations Challenges and Disadvantages Cant produce batches of CSPs in excess of 250 units Can supply compounded medications only under patient-specific conditions Patients often have to cover medication costs out-of-pocket Not subject to the same batch test release requirements under federal cGMP, but expected to ensure quality through USP- and/or state board of pharmacy-compliant procedures and documentation Can a 503A Pharmacy Purchase Products Compounded by a 503B Facility
